Management of a patient with factor X deficiency with FEIBA: a case report

Luish Borboruah; Anupam Dutta

doi:10.2478/jhp-2023-0012

Abstract

Abstract

Hereditary factor X (FX) deficiency is a rare autosomal recessive disorder that increases bleeding tendencies, ranging from epistaxis to intracranial haemorrhage (ICH), which can be life-threatening. Single factor concentrates are recommended for treating rare bleeding disorders; however, in India most people with FX deficiency are treated with fresh frozen plasma (FFP). We report a case of FX deficiency in a child with a history of intracranial bleeding who was found to have a novel mutation in the F10 gene. Although managed with weekly prophylactic FFP infusions, he continued to experience regular bleeding including two further instances of ICH. Other therapeutic options were unavailable or unaffordable. When the Indian Government added FEIBA to the essential drug list, a decision was made to try FEIBA prophylaxis to better manage his bleeding. In 2019, he was started on a weekly dose of FEIBA, 500 IU (20 IU/ kg and his prophylactic FFP transfusion regimen was stopped. His bleeding episodes started to reduce after two months of starting FEIBA prophylaxis. Over the last three years he has had only four minor bleeding episodes and has remained completely free of major bleeding. He is now able to receive home-based therapy and his prognosis can be considered to be improved. FEIBA may be a useful medicinal therapy for FX-deficient patients who suffer severe haemorrhagic episodes in countries where plasma-derived factor X (pdFX) is not available.

Article

View Full Article

References

1. Peyvandi F, Mannucci PM, Lak M, et al. Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. Br J Haematol 1998; 102: 626-628. doi: 10.1046/j.1365-2141.1998.00806.x.
2. Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood 2015; 125: 2052-2061. doi: 10.1182/blood-2014-08-532820.
3. Al-Mouqdad M, Abdelrahim A, Kahlon BMM, Almahmoud L, Asfour S. A successful treatment of infant who had two significant intracranial hemorrhage with factor X replacement: case report. Neonat Pediatr Med 2018; 4: 163. doi: 10.4172/2572-4983.1000163.
4. Escobar MA. Advances in the treatment of inherited coagulation disorders. Haemophilia 2013; 19: 648-659. doi: 10.1111/hae.12137.
5. Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost 2009; 35: 407-415. doi: 10.1055/s-0029-1225763.
6. Powell JS, Rodgers GM. Inherited coagulation disorders. In: Greer JP, Arber DA, Glader B, et al. (eds.). Wintrobe’s Clinical Hematology. 13th edn. 2014. Philadelphia: Lippincott Williams & Wilkins.1143-1185.
7. World Federation of Hemophilia. Report on the Annual Global Survey 2021. October 2022. Available from https://www1.wfh.org/publications/files/pdf-2324.pdf (accessed 10 June 2023).
8. Shah NM, Patel AP. An analysis of 8 cases of factor X deficiency. Indian J Hematol Blood Transfus 2008; 24 (1): 23-25. doi: 10.1007/s12288-008-0018-7.
9. Sinha S, Barik S. Factor X deficiency: a rare case of inherited coagulation disorder presenting as hemarthrosis. Int J Med Res Rev 2014; 2(3): 253-255. doi:10.17511/ijmrr.2014.i03.14.
10. Chatterjee T, Philip J, Nair V, et al. Inherited factor X (Stuart-Prower factor) deficiency and its management. Med J Armed Forces India 2015; 71 (suppl 1): S184-S186. doi: 10.1016/j. mjafi.2014.01.007.
11. Peyvandi F, Auerswald G, Austin SK, et al. Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency. Blood Rev 2021; 50: 100833. doi: 10.1016/j.blre.2021.100833.
12. Mumford AD, Ackroyd S, Alikhan R, et al. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014; 167: 304-26. doi: 10.1111/bjh.13058.
13. Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia 2004; 10 Suppl 2: 3-9. doi: 10.1111/j.1365-2516.2004.00934.x.
14. Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders—review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia 2004; 10: 593-628. doi: 10.1111/j.1365-2516.2004.00944.x.
15. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10: 615-21. doi: 10.1111/j.1538-7836.2012.04653.x.
16. Peyvandi F, Di Michele D, Bolton-Maggs PH, et al. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost 2012; 10: 1938-43. doi: 10.1111/j.1538-7836.2012.04844.x.
17. Shinohara K, Adachi M, Matsui K, et al. A case of factor X (FX) deficiency due to novel mutation V196M, FX Hofu. Int J Hematol 2008; 87(3): 256-259. doi: 10.1007/s12185-008-0035-1.
18. Peyvandi F, Menegatti M, Santagostino E, et al. Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency. Br J Haematol 2002; 117: 685-692. doi: 10.1046/j.1365-2141.2002.03486.x.
19. Telfer TP, Denson KW, Wright DR. A ‘new’ coagulation defect. Br J Haematol 1956; 2(3): 308-316. doi: 10.1111/j.1365-2141-1956.tb06703.x.
20. Hougie C, Barrow EM, Graham JB. Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called stable factor (SPCA, proconvertin, factor VII) deficiency. J Clin Invest 1957; 36: 485-496. doi: 10.1172/JCI103446.
21. Redely SV, Zhou ZQ, Rao KJ, Scott JP, Watzke H, High KA, Jagadeeswaran P. Molecular characterization of human factor XSan.Antonio. Blood 1989; 74(5): 1486-90. doi: 10.1182/blood. V74.5.1486.1486.
22. James HL, Girolami A, Fair DS. Molecular defect in coagulation factor XFriuli results from a substitution of serine for proline at position 343. Blood 1991; 77: 317-323. doi: 10.1182/blood.V77.2.317.317.
23. Ermis B, Ors R, Tastekin A, Orhan F. Severe congenital factor X deficiency with intracranial bleeding in two siblings. Brain Dev 2004; 6: 137-138. doi: 10.1016/S0387-7604(03)00119-0.
24. Sandler E, Gross S. Prevention of recurrent intracranial hemorrhage in a factor X-deficient infant. Am J Pediatr Hematol Oncol 1992; 14: 163-165. doi: 10.1097/00043426-199205000-00012.
25. el Kalla S, Menon NS. Neonatal congenital factor X deficiency. Pediatr Hematol Oncol 1991; 8: 347-354. doi: 10.3109/08880019109028808.
26. Shim YJ, Won DI. Pharmacokinetics and prophylactic use of FEIBA ® in a child with severe congenital factor X deficiency and recurrent spontaneous intracranial haemorrhage: a case report. Haemophilia 2013; 19(6): e364–7. doi: 10.1111/hae.12245.

PDF Download

Download PDF

Open in full-page viewer

Authors

Luish Borboruah

luishborboruah128@gmail.com

Assam Medical College and Hospital, Dibrugarh, India
Anupam Dutta

Assam Medical College and Hospital, Dibrugarh, India